Home » Stocks » CLGN

CollPlant Biotechnologies Ltd. (CLGN)

Stock Price: $14.59 USD 0.12 (0.83%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
Market Cap 94.35M
Revenue (ttm) 6.02M
Net Income (ttm) -7.26M
Shares Out 6.96M
EPS (ttm) -1.11
PE Ratio n/a
Forward PE 96.15
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $14.59
Previous Close $14.47
Change ($) 0.12
Change (%) 0.83%
Day's Open 14.26
Day's Range 14.00 - 14.66
Day's Volume 8,761
52-Week Range 6.24 - 15.76

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
PRNewsWire - 2 months ago

REHOVOT, Israel, Nov. 10, 2020 /PRNewswire/ -- CollPlant (NASDAQ: CLGN) a regenerative medicine company, today announced its development program of an antiviral agent for potential treatment o...

PRNewsWire - 4 months ago

REHOVOT, Israel, Sept. 16, 2020 /PRNewswire/ -- CollPlant (NASDAQ: CLGN) a regenerative and aesthetic medicine company, today announced that Dr.

PRNewsWire - 4 months ago

REHOVOT, Israel, Aug. 31, 2020 /PRNewswire/ -- CollPlant (NASDAQ: CLGN) a regenerative and aesthetic medicine company, today announced that Dr.

PRNewsWire - 4 months ago

REHOVOT, Israel, Aug. 28, 2020 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetics medicine company, today announced financial results for the second quarter ended June 30,...

Zacks Investment Research - 7 months ago

Is (CLGN) Outperforming Other Medical Stocks This Year?

Zacks Investment Research - 7 months ago

Is (CLGN) Outperforming Other Medical Stocks This Year?

Zacks Investment Research - 7 months ago

CollPlant Holdings Ltd. Sponsored ADR (CLGN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects.

PRNewsWire - 7 months ago

REHOVOT, Israel, May 27, 2020 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetics medicine company, today announced financial results for the first quarter ended March 31, ...

Zacks Investment Research - 9 months ago

As of late, it has definitely been a great time to be an investor in CollPlant Biotechnologies.

InvestorPlace - 10 months ago

These healthcare stocks have great financials now, and in the future. They all represent the future of medicine, and offer big growth.

Other stocks mentioned: DGX, DVA, NTRA, NVO, RMD, ZTS
Zacks Investment Research - 1 year ago

CollPlant Holdings Ltd. Sponsored ADR (CLGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.

Zacks Investment Research - 1 year ago

Top Ranked Momentum Stocks to Buy for October 11th

Other stocks mentioned: AMWD, CDE, CMPR

About CLGN

CollPlant Biotechnologies, a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bio-printing of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. The company's products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. Its products include BioInks for 3D printing of tissues and organs; dermal filler for treating wrinkles; 3D Bioprinted breast implants; VergenixSTR, a soft tissue repair matrix intended for... [Read more...]

Industry
Biotechnology
Founded
2004
CEO
Yehiel Tal
Employees
38
Stock Exchange
NASDAQ
Ticker Symbol
CLGN
Full Company Profile

Financial Performance

In 2019, CLGN's revenue was $2.32 million, a decrease of -53.77% compared to the previous year's $5.01 million. Losses were -$11.16 million, 78.7% more than in 2018.

Financial Statements

Analyst Forecasts

According to one analyst, the rating for CLGN stock is "Buy" and the 12-month stock price forecast is 14.00.

Price Target
$14.00
Analyst Consensus: Buy